Lupin Partners with Spektus Pharma to Launch DeslaFlex Antidepressant in Canada
Lupin has signed a license and supply agreement with Spektus Pharma to commercialize DeslaFlex, a novel antidepressant for Major Depressive Disorder, in Canada, strengthening its CNS portfolio.
Drug firm Lupin has inked a license and supply agreement with Spektus Pharma to commercialise the novel antidepressant DeslaFlex in Canada. The strategic partnership combines the company's strong commercial footprint in Canada and Spektus's capabilities in developing differentiated, novel formulations to successfully introduce DeslaFlex and establish a robust platform for future launches.
The collaboration further strengthens Lupin's CNS portfolio with physician-endorsed, value-added therapies, well aligned with a supportive regulatory environment. The addition of DeslaFlex to Lupin's portfolio provides patients and clinicians with flexibility in the management of Major Depressive Disorder, enabling clinicians to deliver more personalised, patient-focused care, according to the President of Global Specialty at Lupin.
The CEO of Spektus Pharma stated that Lupin's global brand and established commercial strength in Canada make it an ideal partner to realise the full value of DeslaFlex for patients across the important market.
Lupin shares ended 0.97 per cent up at Rs 2,220.50 apiece on BSE.